Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study finds
Experts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...
MedPage Today1mon
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...
Medical Dialogues10d
GLP-1 drug shows little benefit for people with Parkinson’s disease: Study
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...
Hosted on MSN2mon
Vivani begins exenatide implant trial for obesity in Australia
Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...
Medscape8d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
KHQ1mon
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as ...